Loading...
ACB logo

Aurora Cannabis Inc.NasdaqCM:ACB Stock Report

Market Cap US$241.9m
Share Price
n/a
1Y-23.2%
7D-5.3%
1D0.3%
Portfolio Value
​
View

Aurora Cannabis Inc.

NasdaqCM:ACB Stock Report

Market Cap: US$241.9m

Aurora Cannabis (ACB) Stock Overview

Engages in the production, distribution, and sale of cannabis products in Canada and internationally. More details

ACB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 77.3% below our estimate of its fair value

Earnings are forecast to grow 101.82% per year

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for ACB from our risk checks.

ACB Community Fair Values

Create Narrative

See what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,300 investors already sharing narratives
View all narratives

Aurora Cannabis Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aurora Cannabis
Historical stock prices
Current Share PriceCA$3.74
52 Week HighCA$6.67
52 Week LowCA$2.56
Beta1.45
1 Month Change1.63%
3 Month Change26.78%
1 Year Change-23.20%
3 Year Change-61.95%
5 Year Change-94.36%
Change since IPO-90.04%

Recent News & Updates

Recent updates

Seeking Alpha • Nov 06

Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy

Summary Aurora Cannabis reported Q2/FY2026 results largely in line with expectations previously outlined by management. High-margin medical cannabis revenue increased by 15% year-over-year and 9% quarter-over-quarter, driven by strong sales in Germany and Poland. On the flip side, sales in Australia declined for a second consecutive quarter due to increasing competition. The disappointing performance resulted in the requirement to take a sizeable impairment charge. While not everything is going according to plan, management remained constructive on the company's near-term outlook and guided for record Adjusted EBITDA in Q3. As a result, I am increasing my price target from $5.65 to $6.30. Given more than 40% upside from current levels and expectations for solid growth in medical cannabis sales, I am upgrading the stock from "Hold" to "Buy". Read the full article on Seeking Alpha
Seeking Alpha • Feb 22

Aurora Cannabis: This Phoenix Has Risen From The Ashes (Strong Buy Initiation)

Summary Aurora Cannabis has transformed its margins, market position, and balance sheet over the last few years, and the stock is now highly 'investible'. ACB's strategic focus on the global medical cannabis market has led to gross margin growth and reduced competition, enhancing top and bottom-line results. The stock is trading at an extremely attractive multiple, and we see significant upside if ACB continues to execute and market awareness of the story improves. We initiate coverage on ACB with a 'Strong Buy' rating. Read the full article on Seeking Alpha
Seeking Alpha • Aug 08

Aurora Cannabis: Revving Up To Profitability

Summary Aurora Cannabis achieves milestone positive free cash flow for the first time in Q1 FY2025. Strong growth in medical cannabis, particularly in Australia and Europe, positions the company well for future profitability. Potential US rescheduling of cannabis could impact Aurora's stock price and open up opportunities in the US market. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Aurora launches new cannabis products for adult and medical-use

Aurora Cannabis (NASDAQ:ACB) is trading ~2% higher after it announced its fall lineup of cannabis products. The products include three unique and proprietary strains -Electric Honeydew, Ultra Grape Kush and Organic BC White Grape OG. The fall product release is set to roll out to patients on Aurora Medical starting in October. "This extensive line up of flower innovation was made possible from Aurora's differentiated consumer preference mapping, which uniquely plots evolving cannabis preferences, and the leading work of R&D to develop a portfolio of products with the critical components necessary to compete – intense and exciting aromas, key visual and tactile attributes, and high-potency THC," the company said.
Seeking Alpha • Oct 07

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Aurora Cannabis (NASDAQ:ACB) has repurchased approximately C$31.3M (US$23M) principal amount of its convertible senior notes at a 5.45% discount to par value, at a total cost, including accrued interest, of C$29.8M in cash. The purpose of the transaction was to reduce the company's debt and annual cash interest costs. Annual cash interest savings from the repurchases of notes made from Q3 2022 onwards now total approximately C$11.9M. The company's balance sheet remains amongst the strongest in the industry, with approximately $380M of cash and cash equivalents. The company reiterates its expectation of achieving a positive Adjusted EBITDA run rate by December 31, 2022. Shares up 4.5% PM. Also read: Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review

Shareholder Returns

ACBUS PharmaceuticalsUS Market
7D-5.3%-3.4%-1.0%
1Y-23.2%44.7%14.1%

Return vs Industry: ACB underperformed the US Pharmaceuticals industry which returned 44.7% over the past year.

Return vs Market: ACB underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is ACB's price volatile compared to industry and market?
ACB volatility
ACB Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: ACB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ACB's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20131,028Miguel Martinwww.auroramj.com

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services.

Aurora Cannabis Inc. Fundamentals Summary

How do Aurora Cannabis's earnings and revenue compare to its market cap?
ACB fundamental statistics
Market capUS$241.86m
Earnings (TTM)-US$37.84m
Revenue (TTM)US$226.52m
1.1x
P/S Ratio
-6.4x
P/E Ratio

Is ACB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACB income statement (TTM)
RevenueCA$314.07m
Cost of RevenueCA$175.33m
Gross ProfitCA$138.74m
Other ExpensesCA$191.21m
Earnings-CA$52.47m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin44.18%
Net Profit Margin-16.71%
Debt/Equity Ratio0%

How did ACB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 01:43
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurora Cannabis Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frederico Yokota Choucair GomesATB Cormark
Etienne RicardBMO Capital Markets Equity Research
Tamy ChenBMO Capital Markets Equity Research